Literature DB >> 7535369

Hepatitis C virus-associated glomerulonephritis. Effect of alpha-interferon therapy.

R J Johnson1, D R Gretch, W G Couser, C E Alpers, J Wilson, M Chung, J Hart, R Willson.   

Abstract

Hepatitis C virus (HCV) infection may present as a primary glomerular disease. We report 34 adult patients who presented with proteinuria and had circulating anti-HCV antibodies. Primary risk factors included a history of intravenous drug abuse (56%) or blood transfusion (18%). Patients presented with nephrotic syndrome (71%) or with non-nephrotic proteinuria (29%) and had membranoproliferative or acute proliferative glomerulonephritis on renal biopsy. Signs of clinical liver disease were infrequent (18%), though elevated liver function tests were common (66%) and liver biopsy in 16 of 18 patients showed chronic active hepatitis. Cryoglobulinemia was frequent (59%), but only 44% had extrarenal manifestations. In 100% of cases tested, HCV RNA could be found in the serum or cryoprecipitates. Fourteen patients received interferon alpha for 6 to 12 months with a significant reduction in proteinuria but no improvement in renal function. A good clinical response correlated with disappearance of HCV RNA from the serum during treatment; however, relapse of viremia and renal disease was common after completing therapy. Evidence for HCV infection should be sought in all patients with primary glomerular disease. The optimal treatment strategy, however, remains to be defined.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7535369     DOI: 10.1038/ki.1994.471

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  32 in total

Review 1.  Extrahepatic manifestations of chronic viral hepatitis.

Authors:  N T Pyrsopoulos; K R Reddy
Journal:  Curr Gastroenterol Rep       Date:  2001-02

2.  Collapsing focal segmental glomerulosclerosis with recovery of renal function: an uncommon complication of interferon therapy for hepatitis C.

Authors:  D F Stein; A Ahmed; V Sunkhara; W Khalbuss
Journal:  Dig Dis Sci       Date:  2001-03       Impact factor: 3.199

3.  The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection.

Authors:  Parag Mahale; Eric A Engels; Ruosha Li; Harrys A Torres; Lu-Yu Hwang; Eric L Brown; Jennifer R Kramer
Journal:  Gut       Date:  2017-06-20       Impact factor: 23.059

Review 4.  Hepatitis C as a systemic disease: virus and host immunologic responses underlie hepatic and extrahepatic manifestations.

Authors:  Chiaki Okuse; Hiroshi Yotsuyanagi; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2007-11-22       Impact factor: 7.527

Review 5.  Mode of hepatitis C virus infection, epidemiology, and chronicity rate in the general population and risk groups.

Authors:  H L Tillmann; M P Manns
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

6.  KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2018-09-19

Review 7.  Global epidemiology and burden of HCV infection and HCV-related disease.

Authors:  Aaron P Thrift; Hashem B El-Serag; Fasiha Kanwal
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-12-07       Impact factor: 46.802

Review 8.  Oculo-renal disorders in infectious diseases.

Authors:  Hassane Izzedine; Irina Buhaescu; Bahram Bodaghi; Valerie Martinez; Eric Caumes; Phuc Lehoang; Gilbert Deray
Journal:  Int Ophthalmol       Date:  2006-03-07       Impact factor: 2.031

Review 9.  [Virus associated glomerulonephritis].

Authors:  H L Tillmann; A Schwarz
Journal:  Internist (Berl)       Date:  2003-09       Impact factor: 0.743

Review 10.  Rituximab as a therapeutic tool in severe mixed cryoglobulinemia.

Authors:  Dario Roccatello; Simone Baldovino; Daniela Rossi; Osvaldo Giachino; Morteza Mansouri; Carla Naretto; Debora Di Simone; Simona Francica; Roberto Cavallo; Mirella Alpa; Franca Napoli; Luigi M Sena
Journal:  Clin Rev Allergy Immunol       Date:  2008-02       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.